FDA
-
-
-
-
-
-
-
Ligand Reports Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Granted EU Approval for Enrylaze
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) and Zymeworks (ZYME) Present Positive Pivotal Phase 2b Trial Data
-
-
-
-
-
-
-
Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting
-
-
-
-
-
-
-
Avadel Pharma (AVDL) Announces Favorable Ruling on Motion to Delist REMS Patent from FDA’s Orange Book
-
-
-
-
-
-
-
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
-
-
-
-
-
-
-
Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine
-
249,491 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All